The adjustment in price target by a major analyst like Wells Fargo can have a mixed impact on Affimed's stock. While maintaining an Overweight rating indicates a positive outlook, the reduction in price target could signal a tempered expectation for the stock's performance in the short term. Investors may react to the lowered price target by adjusting their expectations, but the continued positive rating suggests underlying confidence in the company's fundamentals.